The company made this announcement after market hours on Friday, 9 December 2011.
Meanwhile, the BSE Sensex was up 86.31 points, or 0.53% to 16,299.77.
On BSE, 2,819 shares were traded in the counter as against average daily volume of 78,628 shares in the past one quarter.
The stock hit a high of Rs 523 and a low of Rs 517 so far during the day. The stock had hit a record high of Rs 539.90 on 5 December 2011. The stock had hit a 52-week low of Rs 392.05 on 9 February 2011.
The stock had outperformed the market over the past one month till 9 December 2011, gaining 4.22% compared with the Sensex's 6.62% fall. The scrip had also outperformed the market in past one quarter, rising 6.09% as against 3.87% decline in the Sensex.
India's biggest pharmaceutical company by market capitalisation has an equity capital of Rs 103.56 crore. Face value per share is Re 1.
Sun Pharmaceutical Industries said the generic Tramadol hydrochloride extended release tablets, 100 milligram (mg), 200 mg and 300 mg, are therapeutically equivalent to Ultram ER tablets of Valeant. These tramadol HCL ER tablets have annual sales of approximately $125 million in United States, Sun Pharma said in a statement. Tramadol HCL ER tablets are indicated for management of moderate to moderately severe chronic pain in adults who need around-the-clock treatment of their pain for an extended period of time.
On a consolidated basis, Sun Pharmaceutical Industries' net profit rose 18.7% to Rs 597.74 crore on 42.3% spurt in net sales to Rs 1894.60 crore in Q2 September 2011 over Q2 September 2010.
Sun Pharmaceutical Industries is an international specialty pharma company, with a large presence in the US and India, and a footprint across 40 other markets. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, orthopedics and ophthalmology.
Powered by Capital Market - Live News
